Stratos Wealth Partners LTD. Cuts Stock Position in Edwards Lifesciences Corporation $EW

Stratos Wealth Partners LTD. reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 20.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,517 shares of the medical research company’s stock after selling 2,737 shares during the period. Stratos Wealth Partners LTD.’s holdings in Edwards Lifesciences were worth $823,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth $27,000. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences during the 2nd quarter worth $28,000. Tradewinds Capital Management LLC increased its position in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after buying an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new stake in Edwards Lifesciences in the first quarter valued at about $29,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of several recent analyst reports. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, July 25th. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. William Blair raised Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Truist Financial boosted their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Finally, Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $87.06.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $76.73 on Thursday. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.05 billion, a PE ratio of 11.04, a price-to-earnings-growth ratio of 3.65 and a beta of 1.05. The business has a 50-day simple moving average of $77.44 and a 200-day simple moving average of $76.25.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 earnings per share. On average, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.